x
Filter:
Filters applied
- JLR Patient-Oriented and Epidemiological Research
- prognosisRemove prognosis filter
Publication Date
Please choose a date range between 2016 and 2018.
JLR Patient-Oriented and Epidemiological Research
2 Results
- Patient-Oriented and Epidemiological ResearchOpen Access
Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients
Journal of Lipid ResearchVol. 59Issue 9p1729–1737Published online: June 1, 2018- Sharda Anroedh
- Mika Hilvo
- K. Martijn Akkerhuis
- Dimple Kauhanen
- Kaisa Koistinen
- Rohit Oemrawsingh
- and others
Cited in Scopus: 74We investigated the associations of ten previously identified high risk molecular lipid species and three ceramide ratios with the occurrence of major adverse cardiac events (MACEs) during a median follow-up of 4.7 years in patients with coronary artery disease (CAD). Between 2008 and 2011, 581 patients underwent diagnostic coronary angiography or percutaneous coronary intervention for stable angina pectoris (SAP) or acute coronary syndrome (ACS). Blood was drawn prior to the index procedure and lipid species were determined. - Patient-Oriented and Epidemiological ResearchOpen Access
ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia
Journal of Lipid ResearchVol. 57Issue 6p1059–1073Published online: April 25, 2016- Judit Cubedo
- Teresa Padró
- Rodrigo Alonso
- Pedro Mata
- Lina Badimon
Cited in Scopus: 16HDL composition rather than HDL-cholesterol (HDL-C) levels seems to be a key determinant of HDL-induced atheroprotection. Heterozygous familial hypercholesterolemia (FH) patients, with lifelong exposure to high LDL levels, show a high prevalence of premature coronary artery disease. We hypothesized that HDL of FH patients might have a modified protein composition and investigated the proteomic signature of HDL obtained from FH patients and their unaffected relatives. HDLs were characterized by 2D electrophoresis/MS in 10 families from the SAFEHEART cohort (3 individuals/family: 2 with genetic FH diagnosis and 1 non-FH relative) clinically characterized and treated as per guidelines.